Fibroproliferative mechanisms in organ fibrosis

National Institute On Alcohol Abuse And Alcoholism

Investigators

Linked publications & trials

Abstract

The Section on Fibrotic Disorders (SFD) is established in January 2021. There are three major lines of research in this project as detailed below. Exploring multi-target therapeutic approach for improving efficacy in fibrotic disorders For multifactorial chronic diseases, such as fibrosis, simultaneous targeting of multiple pathways has been recommended as a way to improve therapeutic efficacy. Previously, we identified simultaneous dual-targeting cannabinoid receptor 1 (CB1R) and inducible nitric oxide synthase (iNOS) for inhibition by an in-house generated hybrid inhibitor provided improved antifibrotic efficacy in liver (Cinar et al., 2016 JCI Insight, PMID:27525312) and lung fibrosis (Cinar et al., 2017 JCI Insight, PMID:28422760) compare to inhibiting single target. In collaboration with NHGRI scientists, we found that overactivity of CB1R and iNOS contributes to Hermansky-Pudlak syndrome pulmonary fibrosis, which is a rare genetic disorder with poor progression and high mortality, development and progression via multiple critical pathological process including dysregulation of mitochondrial function and interleukin-11 (IL-11). Our findings also uncovered previously unrecognized role of iNOS regulating IL-11 in pulmonary fibroblast activation and fibrosis. Furthermore, our research identified that simultaneous inhibition of lung CB1R and iNOS by a hybrid inhibitor (MRI-1867) is a rational therapeutic strategy for achieving therapeutic efficacy in HPSPF with attenuating fibrosis, improving pulmonary function and survival. These findings have been published in current report period in Clinical and Translational Medicine (Cinar et al, 2021 PMID:34323400). Exploring role of cannabinoid CB1Rs in lung injury and fibrosis Previously we demonstrated that overactivity of endocannabinoids/CB1R system contributes development of Idiopathic Pulmonary Fibrosis (Cinar et al., 2017 JCI Insight, PMID:28422760) or Hermansky-Pudlak syndrome pulmonary fibrosis (Cinar et al, 2021 PMID:34323400). Additionally, we identified CB1R as a therapeutic target in pulmonary fibrosis. However, cell specific roles of CB1R in lung has not been known yet. One of our major research projects focuses on understanding role of endocannabinoids/CB1R system in lung injury and pulmonary fibrosis. Currently, we are working on developing conditional CB1R knock-out mice with deleting CB1R in different lung cells using Cre-Lox system to test these mutant mice in bleomycin-induced pulmonary fibrosis model. Outcomes of this reseach could uncover cell specific roles of CB1R in lungs during injury and fibrosis. Besides, this research may also identify specific therapeutic modality considering drug delivery route to improve safety and efficacy. Exploring impact of chronic alcohol drinking in lung health Chronic alcohol drinking induces tissue injury in multiple organs including lungs. Accordingly, chronic alcohol drinking predisposes lungs to the development of acute lung injury, pneumonia, and alcoholic lung disease. It is known that chronic alcohol ingestion alters the function of alveolar macrophages (AM). One of our projects explore alcohol impact on lung immunity, immunometabolism and pulmonary function in experimental murine models. We are currently testing available animal models of alcohol drinking, which also induce an injury in lungs beside other organs like liver. Outcomes of our research help us to understand impact of alcohol drinking in lung pathophysiologies.